Patient Power: How Do the Latest Myeloma Treatment Approvals Affect Newly Diagnosed Patients?
Last year, multiple myeloma experienced unprecedented progress, as four new drugs were approved. You can read about that at Holiday Blessings for Myeloma Patients? Now More Than Ever! and Washington Post: For Multiple Myeloma Community, a November to Remember. For the newly-diagnosed patient, what do these new treatment options mean for them? Does one's transplant options matter anymore? For Patient Power, myeloma patient and advocate, Jack Aiello, asked multiple myeloma experts John Burke, MD and Faith Davies, MD, MBBCh, MRCP, FRCPath. You can watch the interview here:How Are Newly Diagnosed Myeloma Patients Affected by the Latest Treatment Approvals? from Patient Power on Vimeo. Interview highlights Dr. Burke said summarizes a study that compared an existing standard two-drug combo (Revlimid and dex) compared with a three-drug combo (Revlimid, dex and Velcade), the three-drug combo "won," with an improved overall survival and progress-free survival in patients. He believes that most oncologists will begin favoring the three-drug regimen in transplant-ineligible patients. Dr. Davies says:
... [if patients] do have a transplant as part of that initial therapy, if [they're] young enough or fit enough to be able to tolerate that, that the response to the therapy is much improved and that that, again, translates to a better outcome. And importantly, they did some very, I can say, sensitive and posh testing to see how low and how little myeloma they could find in these patients. And they could see that in some patients, they couldnt detect any myeloma, even at a level of looking for one myeloma cell in a million normal cells.
To read the entire transcript, click here.